Previous 10 | Next 10 |
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2023 financial results on Wednesday, N...
2023-09-04 12:21:00 ET Needham sees the medtech sector growing by 7% in 2023 versus 5.7% last year, despite slowed growth in Q2, helped by double-digit growth in certain cardiology categories. The investment bank noted that medtech growth slowed slightly in Q2, expanding by only 8.3% co...
2023-08-29 22:32:23 ET Summary AtriCure stock has been heavily sold off following its Q2 numbers, despite strong performance and a revised full-year outlook. The company has seen growth across all segments, with around 20% growth and profits posted at the adj. EBITDA line. Val...
2023-07-25 19:40:03 ET AtriCure, Inc. (ATRC) Q2 2023 Earnings Conference Call July 25, 2023 04:30 PM ET Company Participants Marissa Bych - Vice President-Gilmartin Group Mike Carrel - President & CEO Angie Wirick - CFO Conference Call Participants ...
2023-07-25 16:13:00 ET AtriCure press release ( NASDAQ: ATRC ): Q2 GAAP EPS of -$0.11 beats by $0.19 . Revenue of $100.9M (+19.4% Y/Y) beats by $3.41M . For further details see: AtriCure GAAP EPS of -$0.11 beats by $0.19, revenue of $100.9M beats by $3.41M
Worldwide revenue of $100.9 million – an increase of 19.4% year over year U.S. revenue of $84.9 million – an increase of 19.1% year over year International revenue of $16.0 million – an increase of 20.7% year over year Net loss of $5.1 million – an improvem...
2023-07-09 18:15:18 ET Acumen Pharmaceuticals ( NASDAQ: ABOS ), Establishment Labs ( NASDAQ: ESTA ), Arcus Biosciences ( NYSE: RCUS ) and BridgeBio Pharma ( NASDAQ: BBIO ) are four of BTIG's top picks for small and mid-cap healthcare stocks going into the lat...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release second quarter 2023 financial results on Tuesday, July 2...
2023-06-14 15:43:15 ET Summary AtriCure, Inc. has seen continued momentum in Afib and related markets. The company sees solid revenue growth, which, amidst a retreat in the share price, has resulted in rapidly narrowing sales multiples. While this combination is attractive, I ...
2023-05-29 04:56:42 ET Summary Cryoport continues to grow its top line, while bottom line results are improving. The picture isn't as positive as it initially appears, but progress is still very much welcomed. Even so, the firm still has problems and shares look far too pricey...
News, Short Squeeze, Breakout and More Instantly...
2024-06-19 22:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-19 07:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...